Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib plus paclitaxel vs trastuzumab plus paclitaxel as first-line treatment for HER2+metastatic breast cancer (NEfERTT) - Awada, Ahmad; Colomer, Ramon; Bondarenko, Igor; Inoue, Kenichi; Badwe, Rajendra A.; Demetriou, Georgia; Wang, Xiaojia; Smirnov, Vitaly; Lee, Soo-Chin; Mehta, Ajay O.; Kim, Sung-Bae; Shen, Zhen-Zhou; et al. (Journal Of Clinical Oncology, 2015)